Small Cap Losers: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Altisource Asset Management (NYSEMKT:AAMC), Oncomed Pharmaceuticals (NASDAQ:OMED), Agios Pharmaceuticals (NASDAQ:AGIO)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that data from a Phase 1 study of the selective estrogen receptor modulator (SERM) lasofoxifene were featured in a poster presentation today at ICE/ENDO 2014 in Chicago.  Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) stock performance was -5.92% in last session and finished the day at $62.35. Traded volume was 400.60K shares in the last session and the average volume of the stock remained 275.43K shares. The beta of the stock remained. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) insider ownership is 2.40%.

Altisource Asset Management Corp (NASDAQ:AAMC) major shareholder Luxor Capital Group, Lp bought 2,371 shares of the stock in a transaction dated Friday, May 30th. The shares were purchased at an average cost of $964.35 per share, for a total transaction of $2,286,473.85.  Altisource Asset Management Corp (NYSEMKT:AAMC) dropped -25.40 percent to $819.90 Monday on volume of 76.00K shares. The intra-day range of the stock was $819.90 to $1,037. Altisource Asset Management Corp (NYSEMKT:AAMC) has a market capitalization of $1.84billion.

OncoMed Pharmaceuticals Inc, (NASDAQ:OMED) a clinical stage company, reported on continued discussions begun last week with the US Food and Drug Administration (US FDA) regarding the company’s FZD8-Fc (OMP-54F28) Phase 1 programme. The FDA’s Division of Oncology Products 1 (DOP1) agreed with OncoMed’s voluntary halt, and informed the company that, as a formality, a partial clinical hold has been placed on Phase 1 clinical trials of FZD8-Fc.  Oncomed Pharmaceuticals Inc (NASDAQ:OMED)’s stock on June 23, 2014 reported a decrease of -5.76% to the closing price of $23.09. Its fifty two weeks range is $12.07-$42.34. The total market capitalization recorded $682.54million. The overall volume in the last trading session was 190.30K shares. In its share capital, OMED has 29.56million outstanding shares.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Insider Scott Biller sold 2,004 shares of the company’s stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $50.05, for a total transaction of $100,300.20. Following the completion of the transaction, the insider now directly owns 30,000 shares of the company’s stock, valued at approximately $1,501,500.  On Monday, shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) dropped -11.07% to close the day at $44.02. Company return on investment (ROI) is -30.00% and its monthly performance is recorded as 31.32%. Agios Pharmaceuticals Inc (NASDAQ:AGIO) quarterly revenue growth is 17.48%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone